Mario Balsa· @MarioBalsaMD · X·· 18 小时前评分45
正文 · 机器翻译
‼️ 嗨，#ESMO26 的家人们！
Funda Meric-Bernstam 就 ADC + IO 联合应用背后的理论依据展开了精彩讨论！！ @UTMDAnderson
▪️ADCs 可能诱导免疫原性细胞死亡、释放 DAMPs 并启动 TME
▪️它们还可能提高 PD-L1 表达，有助于克服抗原异质性
▪️VEGF–PD-(L)1 双特异性抗体旨在逆转血管免疫抑制，并改善免疫细胞进入肿瘤的能力
@OncoAlert @OncoReporte @myESMO @_SEOM
121 浏览 · 7 赞 · 5 转发 · 0 回复
会议摘要
1963P按 Investigational immunotherapy 对上
First-in-human phase I study of GB268, a tri-specific antibody targeting PD-1, CTLA-4 and VEGF in advanced solid tumours
https://esmocongress.esmo.org2660P按 NSCLC, metastatic 对上
Phase 2 trial of the PD-1/VEGF bispecific antibody, PF-08634404 (SSGJ-707), plus chemotherapy (chemo) in advanced NSCLC: Updated results
https://esmocongress.esmo.org3636TIP按 Renal cancer 对上
LITESPARK-034: Phase 3 study of belzutifan plus zanzalintinib versus belzutifan in participants with advanced renal cell carcinoma (RCC) during or after anti-PD-(L)1 therapy and VEGF-TKI
https://esmocongress.esmo.org来源：Mario Balsa · x.com